BPC-157 is a synthetic peptide promoted online for tendon, ligament, muscle, gastrointestinal and postoperative healing. It is not an FDA-approved human drug.
Retatrutide is an investigational triple receptor agonist targeting GIP, GLP-1 and glucagon receptors. Multiple Phase 3 studies have reported positive topline results, but FDA has not approved it for any condition.
Semaglutide is a GLP-1 receptor agonist peptide medicine. FDA-approved products now include injection and tablet formulations with product-specific indications spanning type 2 diabetes, cardiovascular risk reduction, chronic weight management and eligible adults with MASH.
A practical checklist for patients trying to distinguish a legitimate prescription and regulated pharmacy from a counterfeit, misbranded, contaminated or research-only product.
A transparent, scope-defined reference to peptide-based medicines with U.S. FDA-approved products. Approval applies only to the product’s labeled indication, formulation and route—not to generalized “anti-aging,” performance or wellness claims.
